Inotropes

Welcome to Audioboards, In this episode, we break down inotropes and vasoactive medications used in the CCU, including dobutamine, milrinone, norepinephrine, dopamine, epinephrine, and levosimendan.

We focus on the physiology behind each drug—cardiac output, SVR, preload, afterload, and perfusion—and when to choose one agent over another in cardiogenic shock.

Transcript

Copy Transcript Copied

Welcome back to AudioBoards. Today we're talking about one of the most important—and most frequently misunderstood—topics in the cardiac ICU: inotropes and vasoactive medications.

When a patient is hypotensive, cold, confused, oliguric, lactate is rising, and the heart is failing, the instinct can be to reach for a pressor or an inotrope. But the important question isn't simply, “Which drug should I start?” The important question is: What is the hemodynamic problem I am trying to fix?

Because an inotrope is not simply a drug that raises the blood pressure. An inotrope primarily increases cardiac contractility and therefore can increase cardiac output. Some drugs also increase vascular tone, while others decrease afterload. So before choosing a drug, think about three things: cardiac output, systemic vascular resistance, and blood pressure.

The fundamental relationship is simple: MAP is approximately cardiac output multiplied by systemic vascular resistance.

And cardiac output is heart rate multiplied by stroke volume.

So if cardiac output is falling because the ventricle cannot generate enough stroke volume, you may need an inotrope. If blood pressure is critically low because systemic vascular resistance is inadequate, you may need a vasopressor. And many patients need both.

This distinction is extremely important in cardiogenic shock.

The modern approach is to use vasoactive medications to restore adequate perfusion while simultaneously treating the underlying cause of shock. Current guidance emphasizes using these medications at the lowest effective dose and for the shortest possible duration, because increasing catecholamine exposure is not a benign intervention.

So let's start with the physiology.

Imagine a patient with severe LV systolic dysfunction. The ventricle is contracting poorly, stroke volume is falling, cardiac output is falling, and tissue perfusion is inadequate. The body responds by activating the sympathetic nervous system. Heart rate rises and systemic vascular resistance increases.

Initially, that helps maintain blood pressure.

But there is a downside.

Increasing systemic vascular resistance increases LV afterload. The failing ventricle now has to pump against a higher pressure. Myocardial oxygen demand increases, coronary perfusion can become compromised, and the cycle of low output and vasoconstriction can become self-perpetuating.

That is why simply pushing the blood pressure higher is not always the same thing as improving perfusion.

The goal is adequate perfusion—not an impressive blood pressure number.

Look at the patient.

Are they cold or warm?

Is the mental status changing?

Is urine output falling?

Is lactate rising?

Is the pulse pressure narrow?

Are the extremities cool?

Are the liver and kidneys showing evidence of hypoperfusion?

And, if you have invasive hemodynamics, what are the cardiac index, filling pressures, pulmonary vascular resistance, and systemic vascular resistance?

Now let's talk about the major medications.

The classic inodilators are dobutamine and milrinone.

Dobutamine is primarily a beta-1 agonist, with beta-2 activity as well. The major effect is increased myocardial contractility, producing an increase in stroke volume and cardiac output. Its beta-2 effect also causes peripheral vasodilation, so systemic vascular resistance can fall.

That combination is why dobutamine is often described as an inodilator.

In practical terms, if your patient has low cardiac output and the blood pressure can tolerate some vasodilation, dobutamine is a very reasonable choice.

Typical dosing is around 2 to 10 micrograms per kilogram per minute, with titration according to the clinical and hemodynamic response. The older literature describes higher doses, but the current principle remains the same: use the lowest dose that achieves the desired effect.

Dobutamine has a very short half-life, which is extremely useful in the ICU. If the patient develops hypotension or tachyarrhythmia, you can rapidly decrease or stop the infusion and its effect dissipates relatively quickly.

But dobutamine is not benign.

It can cause tachycardia and atrial or ventricular arrhythmias. It can increase myocardial oxygen consumption, which matters particularly in active ischemia. It can also produce hypotension because of its vasodilatory effect.

And there is another important clinical issue: chronic beta-blockade can blunt the response to dobutamine.

This is one of the situations where milrinone becomes particularly interesting.

Milrinone is a phosphodiesterase-3 inhibitor.

Instead of directly stimulating the beta receptor, it inhibits PDE-3, increasing intracellular cyclic AMP. In cardiac myocytes, this increases calcium availability and enhances contractility.

But PDE-3 inhibition also occurs in vascular smooth muscle, producing vasodilation.

So once again, milrinone is an inodilator.

The major advantage is that its mechanism is relatively independent of beta-adrenergic receptor stimulation.

So in a patient who is taking a beta-blocker, particularly a patient with advanced chronic heart failure who is now decompensated, milrinone can still produce inotropic and vasodilatory effects.

The usual infusion range is approximately 0.125 to 0.5 micrograms per kilogram per minute in current cardiogenic-shock guidance.

And unlike dobutamine, milrinone is substantially dependent on renal clearance.

That means you need to be careful in renal dysfunction.

A patient with worsening kidney function can accumulate milrinone, leading to prolonged hypotension and arrhythmias. This is particularly important because renal dysfunction is extremely common in cardiogenic shock.

Milrinone also has a longer effective duration than dobutamine, so if the patient becomes hypotensive, you don't have quite the same ability to rapidly turn off its effects.

And this gives us a useful bedside comparison.

Dobutamine: short acting, beta-dependent, relatively easy to titrate.

Milrinone: beta-independent, useful in patients on beta-blockers, but more vasodilatory and more dependent on renal clearance.

But here's the important part: there is no convincing evidence that one is universally superior to the other.

The DOREMI randomized trial enrolled 192 patients with cardiogenic shock and compared milrinone with dobutamine. The primary composite outcome occurred in 49% of patients receiving milrinone and 54% receiving dobutamine, with no statistically significant difference. There were also no significant differences in mortality, mechanical circulatory support, cardiac arrest, or renal replacement therapy.

So don't think of this as “milrinone is better than dobutamine.”

Think of it as:

Choose the physiology and the patient in front of you.

Now let's bring norepinephrine into the conversation.

Norepinephrine is not primarily an inotrope. It is an inopressor.

It has strong alpha-1 activity, producing vasoconstriction and increasing systemic vascular resistance, while beta-1 activity provides some increase in contractility and heart rate.

So if your patient is profoundly hypotensive and you cannot maintain adequate perfusion pressure, norepinephrine is often the first vasoactive medication to reach for.

The current ACC cardiogenic-shock guidance considers norepinephrine a reasonable first choice for most hypotensive patients with cardiogenic shock.

The key is to understand what norepinephrine is doing.

It increases MAP primarily by increasing vascular tone.

That can be lifesaving when coronary and cerebral perfusion pressure are inadequate.

But excessive vasoconstriction increases afterload.

So don't automatically keep escalating norepinephrine just because the blood pressure isn't perfect.

If the underlying problem is profound pump failure, increasing SVR indefinitely can make the failing ventricle work even harder.

This is why a patient with severe cardiogenic shock may need norepinephrine plus an inotrope rather than escalating norepinephrine alone.

Norepinephrine restores vascular tone.

Dobutamine or milrinone improves cardiac output.

That combination addresses two different components of the hemodynamic problem.

Now let's talk about dopamine.

Dopamine has dose-dependent receptor effects.

At lower doses, dopaminergic effects predominate; at intermediate doses, beta-1 effects become more important; and at higher doses, alpha-1-mediated vasoconstriction becomes dominant.

Historically, low-dose dopamine was used with the idea that it would selectively improve renal blood flow and protect the kidneys.

That concept has not held up clinically.

Low-dose dopamine has not consistently improved renal outcomes or decongestion, and it should not be used simply as a “renal-dose dopamine” strategy.

As dopamine doses increase, you get more beta-1 stimulation and eventually more alpha-mediated vasoconstriction.

The problem is that dopamine is relatively arrhythmogenic.

Compared with norepinephrine, dopamine has been associated with more arrhythmias, and data in cardiogenic shock have favored norepinephrine over dopamine.

So in modern practice, dopamine has a much more limited role.

One potentially useful situation is a patient with shock and significant bradycardia where increasing heart rate and cardiac output is part of the immediate problem, but even there, the overall clinical context matters.

Now we need to discuss epinephrine.

Epinephrine is a powerful beta-1, beta-2, and alpha-1 agonist.

It increases contractility.

It increases heart rate.

It increases vascular tone.

And therefore it can dramatically increase cardiac output and blood pressure.

So why isn't epinephrine the default drug for cardiogenic shock?

Because more is not necessarily better.

Epinephrine can cause marked tachycardia, arrhythmias, increased myocardial oxygen demand, hyperglycemia, and lactate elevation.

In cardiogenic shock, studies have also raised concerns about worse metabolic and clinical outcomes compared with norepinephrine-based strategies. The older literature summarized in your source specifically describes more tachycardia, lactic acidosis, arrhythmia, and evidence of gastric hypoperfusion with epinephrine compared with norepinephrine plus dobutamine.

So epinephrine has an important place in resuscitation—especially cardiac arrest—but it is generally not the preferred first-line continuous vasoactive agent for routine cardiogenic shock when alternatives are available.

Now let's talk about levosimendan.

Levosimendan is a calcium sensitizer and also has PDE-3-inhibitory and potassium-channel effects.

Its major conceptual advantage is that it can improve contractility without relying exclusively on increasing intracellular calcium concentration through beta-adrenergic stimulation.

It is therefore particularly interesting in patients who are receiving beta-blockers.

It also causes vasodilation, including pulmonary vasodilation.

That makes it an attractive theoretical option in patients with pulmonary hypertension or elevated pulmonary vascular resistance.

However, levosimendan is not routinely available or routinely used in the United States, and unlike dobutamine or milrinone, it does not have a clear mortality benefit that would make it the universal choice.

Its long-acting active metabolites are also important clinically.

Now let's put everything together with actual patients.

Imagine your first patient.

They have acute MI with severe LV dysfunction.

Blood pressure is 70 over 45.

They are cold.

Lactate is rising.

Urine output is falling.

This is cardiogenic shock until proven otherwise.

The first question is not, “Which inotrope do I like?”

The first question is: How do I restore perfusion while fixing the cause?

This patient needs urgent treatment of the underlying coronary lesion when appropriate, assessment for mechanical circulatory support if shock is refractory, and vasoactive support.

Because the blood pressure is profoundly low, norepinephrine is often a reasonable initial vasoactive agent to restore perfusion pressure. If cardiac output remains inadequate, an inodilator such as dobutamine can be added.

The important concept is that you're not trying to normalize every number.

You're trying to restore adequate tissue perfusion.

Now imagine another patient.

They have advanced chronic HFrEF.

They're taking carvedilol.

They present with low cardiac output, cool extremities, worsening renal function, and a marginal blood pressure.

Here, dobutamine may have a blunted response because of beta-blockade.

Milrinone may be attractive because its mechanism is independent of beta-receptor stimulation.

But if renal function is severely impaired, that advantage has to be weighed against milrinone's renal clearance and longer duration of action.

And if the blood pressure is already marginal, remember that milrinone can vasodilate.

You may therefore need norepinephrine alongside it.

Now imagine a third patient.

They have cardiogenic shock but are relatively hypertensive or normotensive, with a very high systemic vascular resistance and poor cardiac output.

This is where an inodilator makes more physiologic sense.

You don't necessarily need more vasoconstriction.

You need better forward flow and potentially less afterload.

This is the situation where dobutamine or milrinone can be particularly useful.

This leads to a very important principle:

Don't treat the blood pressure alone. Treat the hemodynamic phenotype.

And this becomes even more important when you have a pulmonary artery catheter.

Suppose the patient has low cardiac index, high PCWP, and high SVR.

That's a low-output, congested, vasoconstricted phenotype.

An inodilator may improve forward flow and reduce afterload.

But suppose the patient has low cardiac output and severe hypotension.

Now you may need norepinephrine to establish enough perfusion pressure before or alongside an inotrope.

And suppose the right ventricle is failing.

Now the problem becomes even more complex.

A failing RV is extremely sensitive to increases in pulmonary vascular resistance and changes in preload and afterload.

Milrinone's pulmonary vasodilatory effects can sometimes be attractive in this physiology, but its systemic vasodilation can worsen hypotension.

Again, the answer is not simply “use milrinone.”

It may be milrinone plus norepinephrine, or another carefully selected strategy, depending on the patient's pressure and pulmonary vascular physiology.

Now let's talk about monitoring.

Starting an inotrope should never be the end of the thought process.

You need to know whether the drug is actually helping.

Follow blood pressure and MAP.

Follow heart rate and rhythm continuously.

Look at urine output.

Follow lactate.

Assess mental status and peripheral perfusion.

Look at renal and hepatic function.

If available and appropriate, use echocardiography and invasive hemodynamics to determine whether cardiac output is improving.

And remember that an improvement in blood pressure does not necessarily mean an improvement in cardiac output.

A patient can have a higher MAP because SVR increased while cardiac output actually worsened.

Similarly, a patient can have a higher cardiac output after dobutamine but develop severe tachycardia and myocardial ischemia.

So always ask:

Did perfusion improve?

Not simply:

Did the number improve?

One of the most important mistakes is leaving an inotrope running indefinitely.

These medications are generally intended for short-term stabilization, not routine long-term treatment of acute heart failure.

Chronic or prolonged inotropic therapy is a specialized advanced-heart-failure strategy and may be considered in selected patients as a bridge to transplantation, bridge to mechanical circulatory support, or occasionally as palliative therapy.

But in the acute setting, the goal is to stabilize the patient and then transition away from vasoactive support whenever possible.

And this is where mechanical circulatory support enters the conversation.

If the patient remains in refractory cardiogenic shock despite appropriate pharmacologic therapy, escalating catecholamines indefinitely is not the answer.

Current guidance emphasizes early recognition of refractory shock and consideration of temporary mechanical circulatory support and transfer to experienced shock centers when appropriate.

In other words:

Inotropes are a bridge, not a destination.

That’s all for today’s episode. Thanks for listening to AudioBoards. Stay tuned for more educational content in our next episode! The views and opinions expressed on the AudioBoards Podcast do not necessarily reflect those of our employers. This podcast is for educational purposes only and should not be used to diagnose or treat any medical conditions. It is not a substitute for professional medical advice. Always consult a qualified, board-certified healthcare provider for any medical concerns